Expression Profile, Molecular Association, and Clinical Significance of POLD4 in Glioblastoma

Md Tanjim Alam1, Mohammad Shadab Ali2,3, Harsh Goel2

  • 1Cancer Biology & Inflammatory Disorder Division, CSIR-IICB Translational Research Unit of Excellence, CN-6, Salt Lake, Sector - V, Kolkata, WB, 700091, India.

Insights

The POLD4 gene is highly expressed in glioblastoma (GBM), correlating with poor patient outcomes and immune cell infiltration. This suggests POLD4 may serve as a potential biomarker for GBM diagnosis and prognosis.

Area of Science:

  • Molecular Biology
  • Cancer Genomics
  • Bioinformatics

Background:

  • The POLD4 gene encodes a subunit of DNA polymerase delta, crucial for DNA replication and repair.
  • Emerging evidence links POLD4 to various cancers, but its role in glioblastoma (GBM) remains under-explored.

Purpose of the Study:

  • To investigate the role and potential of POLD4 as a biomarker in glioblastoma using bioinformatics tools.
  • To analyze POLD4 gene and protein expression, methylation status, and its correlation with clinical outcomes and immune infiltration in GBM.

Main Methods:

  • Utilized cancer bioinformatics tools (MEXPRESS, UALCAN, cBioPortal, GSEA) to analyze TCGA-GBM data.
  • Assessed POLD4 gene/protein expression, DNA methylation, immune cell infiltration, and survival outcomes (OS, PFS, DFS).
  • Performed gene correlation and pathway enrichment analysis (GSEA).

Main Results:

  • POLD4 was significantly upregulated at both gene and protein levels in glioblastoma.
  • POLD4 expression correlated positively with DNA methylation at specific CpG sites and was associated with critical oncogenic pathways (e.g., interferon-gamma response, EMT).
  • Elevated POLD4 expression was linked to poor overall survival (OS), progression-free survival (PFS), and disease-free survival (DFS), and altered immune cell infiltration.

Conclusions:

  • POLD4 is a significantly upregulated gene in glioblastoma and shows potential as a diagnostic or prognostic biomarker.
  • POLD4 expression is associated with key cancer-related pathways and adverse clinical outcomes in GBM patients.
  • Further large-scale studies are warranted to validate POLD4's utility as a GBM biomarker.